| Gene symbol | CD5 | Synonyms | LEU1, T1 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD5 molecule | ||||
| GTO ID | GTC3884 |
| Trial ID | NCT06420089 |
| Disease | T Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD5 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Senza5 CART5 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) to Enhance Immunotherapy Against T Cell Non-Hodgkin Lymphoma (NHL): a First-in-human Phase I Clinical Trial |
| Year | 2024 |
| Country | United States |
| Company sponsor | Vittoria Biotherapeutics |
| Other ID(s) | VIPER 101 |
| Cohort 1 | |||||||||||
|
|||||||||||